This is not a moment our community can afford to spend fighting itself,” writes American Diabetes Association CEO Charles ...

A review of findings from a five-person committee is being sent to the ADA board for action, STAT has learned, but it appears unlikely to quiet the controversy.

Late-breaking data for retatrutide, CagriSema, survodutide, and oral elecoglipron are poised to reshape near-term formulary strategy and utilization management for obesity and metabolic disease.

As the 2026 American Diabetes Association (ADA) conference draws to a close for another year, Pharmaceutical Technology gives you a rundown of the key readouts from the obesity segment, which could ...

On the morning of June 5, 2026, attendees queued outside the main hall of the Ernest N. Morial Convention Center in New Orleans for the American Diabetes Association (ADA) Scientific Sessions. The ...

A video from the American Diabetes Association (ADA) 2026 conference made headlines over the weekend, but it wasn’t about a scientific advance. The ADA conference organizers had the police escort five ...

CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that three ...

Findings from CRISPR-edited stem cell–derived islets suggest SMOC1 functions as a physiological stabilizer of NKX6.1-positive β-cell identity. Experts at ADA 2026 say nutrition guidelines must be ...

Wider use of continuous glucose monitoring (CGM), glycemic management during cancer treatment, and individualized dosing of obesity drugs in people with diabetes are just a few of the new topics and ...

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes ...